CTS Corp Beats Q2 Estimates, Lifts 2026 Guidance on Diversified Market Strength
CTS sits 68% above its 52-week low of $36.025.
Summary
CTS Corp delivered a strong Q2, with sales up 7% to $144.8M and adjusted EPS of $0.74, beating the lone analyst estimate of $0.61. The beat was driven by 15% growth in diversified end markets—industrial, aerospace & defense, and medical—offsetting a 2% decline in transportation. Management raised full-year 2026 guidance: sales now seen at $565-$585M (from $560-$580M) and adjusted EPS at $2.55-$2.70 (from $2.35-$2.45). This follows a solid Q1 and a CEO transition in June, with the new leadership already delivering record margins. The stock trades at 23x forward earnings, above its three-month average of 19x, reflecting heightened expectations. The guidance raise signals confidence in sustained diversified-market momentum, though transportation remains a soft spot.
At the time of this announcement, CTS was trading at $60.41 on NYSE in the Manufacturing sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $36.03 to $69.55. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.